Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates

 
• By Mike Ward
  
Generate a summary of this article
Listen to this article
Beta

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus and direction as it reduces its commitment to Belviq. He talked to Mike Ward about progress to date.

Video interview
Arena's CEO Amit Munshi talks to Scrip at Biotech Showcase

In the six months after joining Arena Pharmaceuticals Inc. as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq (lorcaserin), which it has partnered with Eisai Co. Ltd.; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017.

Munshi updates Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, on the company’s progress to date,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.